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osting by EAbstract In modern drug designing, molecular docking is routinely used for understanding drug-
receptor interaction. In the present study six imidazole derivatives containing substituted pyrazole
moiety (2a,b and 4a–d) were synthesized. Structures of the newly synthesized compounds were char-
acterized by spectral studies. Compounds were screened for their antibacterial activity. Compound
4c was found to be potent antimicrobial againstPseudomonas aeruginosa at concentrations of 1 and
0.5 mg/mL compared to standard drug Streptomycin. All the compounds were subjected to molec-
ular docking studies for the inhibition of the enzyme L-glutamine: D-fructose-6-phosphate amido-
transferase [GlcN-6-P] (EC 2.6.1.16). The in silico molecular docking study results showed that,
all the synthesized compounds having minimum binding energy and have good afﬁnity toward
the active pocket, thus, they may be considered as good inhibitor of GlcN-6-P synthase.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.4 2474033.
.M. Isloor).
y. Production and hosting by
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lsevier1. Introduction
Molecular docking may be deﬁned as an optimization prob-
lem, which would describe the ‘‘best-ﬁt’’ orientation of a ligand
that binds to a particular protein of interest and is used to pre-
dict the structure of the intermolecular complex formed be-
tween two or more molecules. The most interesting case is
the protein ligand interaction, because of its applications in
medicines. Ligand is a small molecule, which interacts with
protein’s binding sites. There are several possible mutual con-
formations in which binding may occur. These are commonly
called binding modes (Sharma et al., 2010). In modern drug
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198 A.M. Vijesh et al.designing, molecular docking is routinely used for understanding
drug-receptor interaction. Molecular docking provides useful
information about drug receptor interactions and is frequently
used to predict the binding orientation of small molecule drug
candidates to their protein targets in order to predict the afﬁn-
ity and activity of the small molecule.
Human beings have been in constant exposure to pathogens
for many decades. Invasive microbial infections are major
problems around the world, especially in immuno compro-
mised patients. The recent expansion of antimicrobial drug re-
search has occurred because there is a critical need for new
antimicrobial agents to treat these life threatening invasive
infections. The development of antimicrobial resistance has in-
creased in this century and there is a need for developing new
antimicrobial agents which will be more selective, potent and
less toxic compared to the existing drugs in clinical treatment.
Heterocycles containing an azole ring system are found to ex-
hibit a wide spectrum of biological activities, including anti-
bacterial and antifungal properties. Imidazole and its
derivatives have gained remarkable importance due to their
widespread biological activities and their use in synthetic
chemistry. Imidazole derivatives possess a broad spectrum of
pharmacological activities such as, anti-inﬂammatory (Suzuki
et al., 1992), analgesic, anti-convulsant (Pinza et al., 1993),
antitubercular (Pandey et al., 2009), antimicrobial, anticancer
and anti-Parkinson (Miyachi et al., 1998) activities. Imidazole
and its derivatives are of great signiﬁcance due to their impor-
tant roles in biological systems, particularly in, enzymes as
proton donors and/or acceptors, coordination system ligands
and the base of charge–transfer processes. The imidazole nu-
cleus appears in a number of naturally occurring products like,
amino acids histidine and purines, which comprise many of the
most important bases in nucleic acids.
Similarly pyrazole derivatives have showed signiﬁcant bio-
logical activities, such as anti-microbial (Isloor et al., 2009),
analgesic (Isloor et al., 2000), anti-inﬂammatory (Bekhita and
Abdel-Aziem, 2004) and anticancer (Dhanya et al., 2009) activ-
ities. This gave a great impetus to the search for potential phar-
macologically active drugs carrying pyrazole substituents.
The enzyme, namely glucosamine-6-phosphate synthase
(GlmS, GlcN-6-P synthase,L-glutamine:D-fructose-6P amido-
transferase, EC 2.6.1.16) also known under the trivial name of
glucosamine-6-phosphate synthase, is a new target for antifun-
gals (Chmara et al., 1984). GlcN-6-P synthase catalyzes the ﬁrst
step in hexosamine metabolism, converting fructose 6-phos-
phate (Fru6P) into glucosamine 6-phosphate (GlcN6P) in the
presence of glutamine. The reaction catalyzed by GlmS is irre-
versible, and is therefore considered as a committed step. The
end product of the pathway, N-acetyl glucosamine, is an essen-
tial building block of bacterial and fungal cell walls. Structural
differences between prokaryotic and human enzymes may be
exploited to design speciﬁc inhibitors, whichmay serve as proto-
types of anti-fungal and anti-bacterial drugs (Borowski, 2000).
It has been shown that even a short time inactivation of
GlcN-6-P synthase is lethal for fungal cells, while in mammals
depletion of the amino sugar pool for a short time is not lethal,
because of the much longer lifespan of mammalian cells, long
half lifetime of GlcN-6-P synthase, and rapid expression of the
mammalian gene encoding the enzyme GlcN-6-P synthase
(Milewski et al., 1986). It is well established that small modiﬁ-
cations in the structure of the targets are altering their biolog-
ical character as well as their physiochemical properties. Adetailed literature survey on antimicrobial activity of various
types of compounds indicated that, the presence of certain
pharmacophore such as imidazole/pyrazole in any molecule
plays an important role in enhancing activity. In our previous
paper (Vijesh et al., 2011), we reported the synthesis and the
antimicrobial activity of the imidazole derivatives containing
pyrazole nucleus. In continuation of that, we have performed
the molecular docking studies of the biologically active six
compounds for better understanding of the drug-receptor
interaction.
2. Experimental
2.1. Materials and methods
Melting points were determined by open capillary method
and were uncorrected. The IR spectra (in KBr pellets) were
recorded on a JASCO FT/IR-4100 spectrophotometer. 1H
NMR and 13C NMR spectra were recorded (DMSO-d6)
on a Bruker (400 MHz) using TMS as the internal standard.
Chemical shift values are given in d (ppm) scales. The mass
spectra were recorded on a JEOL JMS-D 300 spectrometer
operating at 70 eV. Elemental analyses were performed on
a Flash EA 1112 series CHNS-O Analyzer. The completion
of the reaction was checked by thin layer chromatography
(TLC) on silica gel coated aluminum sheets (silica gel 60
F254) obtained from Merck. Commercial grade solvents
and reagents were used without further puriﬁcation (see
Scheme 1).
2.2. General procedure for the synthesis of new derivatives of
2,4,5-trisubstituted imidazoles (2a,b)
A mixture of 3-aryl-1H-pyrazole-4-carbaldehyde 1a,b (0.01
mol), benzil (0.01 mol) and ammonium acetate (0.05 mol) in
acetic acid (50 mL) was reﬂuxed for 6–7 h at 120 C. After com-
pletion of the reaction, the reaction mixture was allowed to cool
and ﬁltered to remove any precipitate. 300 mL of ice-water was
added to the ﬁltrate and the precipitated product was collected
by ﬁltration. The crude product was recrystallized using etha-
nol–DMF mixture (Vijesh et al., 2011).
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2.2.1.1. 3-(2,4-Dichlorophenyl)-4-(4,5-diphenyl-1H-imidazol-2-
yl)-1H-pyrazole (2a). IR (KBr, mmax cm
1): 3135 (N–H-str),
3062, 2922 (C–H-str), 1668 (C‚N), 1598 (C‚C); 1H NMR
(400 MHz, DMSO-d6): d 7.14–7.92 (m, 13H, Ar-H), 8.27 (s,
1H, pyrazole-5H), 12.22 (s, 1H, pyrazole–NH), 13.24 (s, 1H,
imidazole–NH); 13C NMR: 194.77, 184.39, 171.94, 140.16,
135.4, 134.5, 133.95, 133.27, 132.22, 131.38, 129.55, 129.46,
128.51, 128.05, 126.55, 120.97, 111.56; MS: m/z= 431.2
(M+), 433.1 (M+2), 435.1 (M+4); Anal. calcd. for
C24H16Cl2N4: C, 66.77; H, 3.71; N, 12.98; Found: C, 66.76;
H, 3.68; N, 12.95%.
2.2.1.2. 4-(4,5-Diphenyl-1H-imidazol-2-yl)-3-(4-methylphenyl)-
1H-pyrazole (2b). IR (KBr, mmax cm
1): 3130 (N–H-str), 3054,
2919 (C–H-str), 1654 (C‚N), 1604 (C‚C); 1H NMR
(400 MHz, DMSO-d6): d 2.07 (s, 3H, CH3), 7.16–7.91 (m,
14H, Ar-H), 7.92 (s, 1H, pyrazole-5H), 12.28 (s, 1H, pyra-
zole–NH), 13.10 (s, 1H, imidazole–NH); 13C NMR: 184.70,
140.62, 137.21, 129.53, 129.44, 128.54, 128.11, 127.91, 127.03,
109.39, 20.98; MS: m/z= 377.2 (M+1); Anal. calcd. for
C25H20N4: C, 79.69; H, 5.31; N, 14.88; Found: C, 79.66; H,
5.28; N, 14.55%.
2.3. General procedure for the synthesis of methyl(2Z)-[3-
({(E)-[3-aryl-1H-pyrazol-4-yl]methylidene}amino)-5-oxo-2-
thioxoimidazolidin-4-ylidene]ethanoate (4a–d)
An equimolar mixture of 3-aryl-1H-pyrazole-4-carbaldehyde
thiosemicarbazone 3a–d (0.01 mol) and dimethylacetylenedi-
carboxylate (DMAD) (0.01 mol) in methanol (20 mL) was re-
ﬂuxed for 1 h. After completion of the reaction, the reaction
mixture was allowed to cool. The solid thus separated was col-
lected by ﬁltration and recrystallized using ethanol–DMF mix-
ture (Vijesh et al., 2011).
2.3.1. Characterization of synthesized compounds
2.3.1.1. Methyl(2Z)-[3-({(E)-[3-(2,4-dichlorophenyl)-1H-
pyrazol-4-yl]methylidene}amino)-5-oxo-2-thioxoimidazolidin-
4-ylidene]ethanoate (4a). IR (KBr, mmax cm
1): 3242 (N–H-
str), 3068, 2951 (C–H-str), 1707 (C‚O ester), 1645 (C‚O cyc-
lic amide), 1607 (C‚N), 1106 (C‚S), 1238, 1195 (C-O ester);
1H NMR (400 MHz, DMSO-d6): d 3.80 (s, 3H, OCH3), 6.58 (s,
1H, C‚CH), 7.41–7.57 (m, 3H, Ar-H), 7.96 (s, 1H, pyrazole-
5H), 8.28 (s, 1H, N‚CH), 12.64 (s, 1H, pyrazole–NH), 13.50
(s, 1H, imidazole–NH); MS: m/z= 423.9 (M+), 425.9 (M+2),
427.9 (M+4); Anal. calcd. for C16H11Cl2N5O3S: C, 45.26; H,
2.59; N, 16.50; Found: C, 45.23; H, 2.57; N, 16.47%.
2.3.1.2. Methyl(2Z)-[3-({(E)-[3-(2,5-dichlorothiophen-3-yl)-
1H-pyrazol-4-yl]methylidene} amino)-5-oxo-2-thioxoimidazoli-Table 1 Characterization data of the compounds 2a,b and 4a–d.
Compound Ar Molecular
2a 2,4-Dichlorophenyl C24H16Cl2
2b 4-Anisyl C25H20N4
4a 2,4-Dichlorophenyl C16H11Cl2
4b 2,5-Dichlorothiophene C14H9Cl2N
4c 4-Thioanisyl C17H15N5O
4d 4-Tolyl C17H15N5Odin-4-ylidene]ethanoate (4b). IR (KBr, mmax cm
1): 3213
(N–H-str), 3051, 2953 (C–H-str), 1713 (C‚O ester), 1640
(C‚O cyclic amide), 1602 (C‚N), 1023 (C‚S), 1247, 1197
(C–O ester); 1H NMR (400 MHz, DMSO-d6): d 3.79 (s, 3H,
OCH3), 6.62 (s, 1H, C‚CH), 7.23 (s, 1H, Ar-H), 8.35 (s, 1H,
pyrazole-5H), 8.38 (s, 1H, N‚CH), 12.71 (s, 1H, pyrazole–
NH), 13.60 (s, 1H, imidazole–NH); 13C NMR: 165.77, 165.65,
151.60, 142.92, 131.66, 128.72, 125.06, 114.89, 114.13, 52.38;
MS: m/z= 430.0 (M+), 432.0 (M+2). 434.0 (M+4); Anal.
calcd. for C14H9Cl2N5O3S2: C, 39.04; H, 2.09; N, 16.27; Found:
C, 39.03; H, 2.06; N, 16.26%.
2.3.1.3. Methyl(2Z)-(3-{[(E)-{3-[4-(methylsulfanyl)phenyl]-
1H-pyrazol-4-yl}methylidene] amino}-5-oxo-2-thioxoimidazoli-
din-4-ylidene)ethanoate (4c). IR (KBr, mmax cm
1): 3121
(N–H-str), 3033, 2950 (C–H-str), 1711 (C‚O ester), 1636
(C‚O cyclic amide), 1598 (C‚N), 1096 (C‚S), 1240, 1188
(C–O ester); 1H NMR (400 MHz, DMSO-d6): d 2.55 (s, 3H,
SCH3), 3.79 (s, 3H, OCH3), 6.65 (s, 1H, C‚CH), 7.40–7.77
(m, 4H, Ar-H), 8.48 (s, 1H, pyrazole-5H), 8.64 (s, 1H,
N‚CH), 12.75 (s, 1H, pyrazole–NH), 13.48 (s, 1H, imidaz-
ole–NH); MS: m/z= 402.0 (M+1); Anal. calcd. for
C17H15N5O3S2: C, 50.81; H, 3.74; N, 17.44; Found: C, 50.79;
H, 3.71; N, 17.41%.
2.3.1.4. Methyl(2Z)-[3-({(E)-[3-(4-methylphenyl)-1H-pyra-
zol-4-yl]methylidene}amino)-5-oxo-2-thioxoimidazolidin-4-yli-
dene]ethanoate (4d). IR (KBr, mmax cm
1): 3241 (N–H-str),
3029, 2950 (C–H-str), 1706 (C‚O ester), 1641 (C‚O cyclic
amide), 1611 (C‚N), 1098 (C‚S), 1240, 1195 (C–O ester);
1H NMR (400 MHz, DMSO-d6): d 2.38 (s, 3H, CH3), 3.80
(s, 3H, OCH3), 6.65 (s, 1H, C‚CH), 7.35–7.65 (m, 4H, Ar-
H), 7.96 (s, 1H, pyrazole-5H), 8.42 (s, 1H, N‚CH), 12.72 (s,
1H, pyrazole–NH), 13.41 (s, 1H, imidazole–NH); MS: m/
z= 370.1 (M+1); Anal. calcd. for C17H15N5O3S: C, 55.23;
H, 4.06; N, 18.95; Found: C, 55.21; H, 4.05; N, 18.93% (see
Table 1).
2.4. Antibacterial studies
The antibacterial activity of newly synthesized compounds
2a–d and 4a–j was determined by well plate method
(Arthington-Skaggs et al., 2000) in Mueller–Hinton Agar.
The in vitro antibacterial activity was carried out against
24 h old cultures of bacterial strains. In this work, Escherichia
coli, Bacillus subtilis, Salmonella typhimorium, Clostridium
proﬁngens and Pseudomonas aeruginosa were used to investi-
gate the activity. The test compounds were dissolved in
dimethyl sulfoxide (DMSO) at concentration of 1 and
0.5 mg/mL. Twenty milliliters of sterilized agar media was
poured into each pre-sterilized Petri dish. Excess of suspensionformula (Mol. wt.) Yield (%) M.p. (C)
N4 (431.3) 72 210–212
(376.4) 68 180–182
N5O3S (424.2) 81 282–284
5O3S 2 (430.2) 86 280–282
3S2 (401.4) 84 230–232
3S (369.3) 80 286–288
T
a
b
le
2
A
n
ti
b
a
ct
er
ia
l
a
ct
iv
it
y
o
f
th
e
co
m
p
o
u
n
d
s
2
a
,b
a
n
d
4
a
–
d
.
C
o
m
p
o
u
n
d
B
a
ci
ll
u
s
su
b
ti
li
s
E
sc
h
er
ic
h
ia
co
li
C
lo
st
ri
d
iu
m
p
ro
ﬁ
n
g
en
s
S
a
lm
o
n
el
la
ty
p
h
im
o
ri
u
m
P
se
d
u
m
o
n
a
s
a
u
re
g
in
o
sa
C
o
n
cn
(l
g
/m
L
)
1
0
0
0
5
0
0
1
0
0
0
5
0
0
1
0
0
0
5
0
0
1
0
0
0
5
0
0
1
0
0
0
5
0
0
2
a
6
±
0
.0
1
5
±
0
.0
1
1
0
±
0
.0
3
9
±
0
.0
2
6
±
0
.0
2
5
±
0
.0
2
3
±
0
.0
2
2
±
0
.0
1
4
±
0
.0
1
3
±
0
.0
2
2
b
8
±
0
.0
1
7
±
0
.0
2
1
4
±
0
.0
2
8
±
0
.0
1
6
±
0
.0
1
5
±
0
.0
2
6
±
0
.0
2
5
±
0
.0
1
6
±
0
.0
1
4
±
0
.0
1
4
a
8
±
0
.0
2
7
±
0
.0
2
8
±
0
.0
1
7
±
0
.0
2
7
±
0
.0
3
6
±
0
.0
3
4
±
0
.0
2
3
±
0
.0
1
7
±
0
.0
1
6
±
0
.0
3
4
b
8
±
0
.0
1
7
±
0
.0
1
9
±
0
.0
1
8
±
0
.0
3
1
2
±
0
.0
1
1
1
±
0
.0
2
1
0
±
0
.0
1
9
±
0
.0
1
9
±
0
.0
3
8
±
0
.0
2
4
c
1
0
±
0
.0
2
9
±
0
.0
2
1
2
±
0
.0
2
9
±
0
.0
2
1
6
±
0
.0
1
1
5
±
0
.0
2
1
2
±
0
.0
1
1
1
±
0
.0
2
1
6
±
0
.0
2
1
5
±
0
.0
2
4
d
9
±
0
.0
1
8
±
0
.0
1
5
±
0
.0
1
4
±
0
.0
1
6
±
0
.0
1
5
±
0
.0
1
6
±
0
.0
1
5
±
0
.0
2
4
±
0
.0
1
3
±
0
.0
1
S
ta
n
d
a
rd
S
tr
ep
to
m
y
ci
n
2
1
±
0
.0
2
1
1
±
0
.0
2
1
6
±
0
.0
2
1
0
±
0
.0
1
1
7
±
0
.0
2
1
6
±
0
.0
1
1
8
±
0
.0
2
1
7
±
0
.0
1
1
3
±
0
.0
2
9
±
0
.0
1
200 A.M. Vijesh et al.was decanted and plates were dried by placing in an incubator
at 37 C for an hour. About 60 lL of 24 h old culture suspen-
sion was poured and neatly swabbed with the pre-sterilized
cotton swabs. Six millimeter diameter well was then punched
carefully using a sterile cork borer and 30 lL of test solutions
of different concentrations were added into each labeled well.
The plates were incubated for 24 h at 37 C. The inhibition
zone that appeared after 24 h, around the well in each plate
were measured as zone of inhibition in mm. Experiments were
triplicates and standard deviation was calculated. The antibac-
terial results were compared with streptomycin and summa-
rized in Table 2.
2.5. In silico molecular docking studies
The ligands were drawn in ChemDraw Ultra 6.0 (ChemOfﬁce
package) assigned with proper 2D orientation and the struc-
ture of each compound was analyzed for connection error in
bond order. OSIRIS, an ADMET based Java library layer that
provides reusable cheminformatics functionality which is an
entirely in-house developed drug discovery informatics system
was used to predict the total drug score via in silico (Sander
et al., 2009). Energy of the molecules was minimized using
Dundee PRODRG2 server (Schuttelkopf and Aalten, 2004).
The energy minimized compounds were then read as input
for AutoDock 4.2, in order to carry out the docking simulation
(Morris et al., 1998). All the heteroatoms were removed from
the2VF5.pdb, to make complex receptor free of any ligand be-
fore docking. The Graphical User Interface program ‘‘Auto-
Dock Tools’’ was used to prepare, run, and analyze the
docking simulations. Kollman united atom charges, solvation
parameters and polar hydrogen’s were added to the receptor
for the preparation of protein in docking simulation. Since li-
gands are not peptides, Gasteiger charge was assigned and
then non-polar hydrogens were merged. AutoDock requires
pre-calculated grid maps, one for each atom type, present in
the ligand being docked as it stores the potential energy arisingFigure 1 Crystal structure of X chain of GlcN-6-P synthase in
complex with glucosamine-6-phosphate.
Figure 2 PDBsum’s ligplot results for 2VF5, showing all 12 amino acid residues of active pocket.
Molecular docking studies of some new imidazole derivatives 201from the interaction with macromolecule. This grid must sur-
round the region of interest (active site) in the macromolecule.
In the present study, the binding site was selected based on the
amino acid residues, which are involved in binding with gluco-
samine-6-phosphate of GlcN-6-P synthase as obtained from
PDB with ID 2VF5 which would be considered as the best
accurate active region as it is solved by experimental crystallo-
graphic data (Mouilleron et al., 2008). Therefore, the grid was
centered at the region including all the 12 amino acid residues
(Ala602, Val399, Ala400, Gly301, Thr302, Ser303, Cys300,
Gln348, Ser349, Thr352, Ser347 and Lys603) that surround ac-
tive site as in Fig. 2. The grid box size was set at 70, 64, and
56 A˚ for x, y and z respectively, and the grid center was set
to 30.59, 15.822 and 3.497 for x, y and z respectively, which
covered all the 12 amino acid residues in the considered active
pocket. Docking software AutoDock 4.2 Program supplied
with AutoGrid 4.0 and AutoDock 4.0 was used to produce
grid maps. The spacing between grid points was 0.375 ang-
stroms. The Lamarckian Genetic Algorithm (LGA) was cho-
sen to search for the best conformers. During the docking
process, a maximum of 10 conformers was considered for each
compound. All the AutoDock docking runs were performed in
Intel Centrino Core2Duo CPU @ 2.20 GHz of IBM system
origin, with 2 GB DDR2 RAM. AutoDock 4.0 was compiled
and run under Microsoft Windows XP operating system.
3. Results and discussion
3.1. Synthesis of imidazole derivatives and characterization
3-Substituted-1H-pyrazole-4-carbaldehydes (1a–d) were syn-
thesized by the Vilsmayer Haack reaction of semicarbazones(Lebedev et al., 2005). 2,4,5-Trisubstituted imidazoles (2a–b)
were obtained in excellent yields by reﬂuxing 3-substituted-
1H-pyrazole-4-carbaldehydes with 1,2-diketone (Benzil) and
ammonium acetate in acetic acid for 6–7 h via Debus reaction
(Vijesh et al., 2011). The imidazolones (4a–d) were obtained
in good yield by reﬂuxing substituted thiosemicarbazones
(3a–d) with dimethylacetylenedicarboxylate (DMAD) in
methanol for 1 h (Vijesh et al., 2011). The starting material
3a–d in turn was synthesized by reﬂuxing equimolar amount
of 3-aryl-1-H-pyrazole-4-carbaldehyde with thiosemicarbazide
in the presence of anhydrous sodium acetate in ethanol. The
reaction pathway has been summarized in Scheme 1. Newly
synthesized compounds (2a,b and 4a–d) were characterized
by IR, NMR, mass spectral and C, H, N elemental analyses.
Formation of 4-(4,5-aryl-1H-imidazol-2-yl)-3-[substituted]
-1H-pyrazole (2a,b) and methyl (2Z)-[3-({(E)-[3-(substituted)-
1H-pyrazol-4-yl]methylidene}amino)-5-oxo-2-thioxoimidazoli-
din-4-ylidene]ethanoate (4a–d) was conﬁrmed by recording their
IR, 1HNMR, 13CNMRandmass spectra. All compounds were
characterized after recrystallization from appropriate solvents.
IR spectrum of compound 4c showed absorption at 3121 cm1
which is due to the NH stretching. Bands at 1711, 1636 cm1
are due to C‚O of ester and cyclic amide respectively. Band
at 1598 cm1 is due to C‚N, band at 1096 cm1 is due to
C‚S group. The C–O stretching frequency of ester appeared
at 1240 cm1 and 1188 cm1 further conﬁrms the structure.
The 1H NMR spectrum of 4c showed a singlet at d 2.55 is due
to SCH3 protons. A singlet at d 3.79 is due to OCH3 protons.
A singlet at d 6.65 is due to C‚CH. Aromatic protons appeared
as multiplet at d 7.40–7.77. Pyrazole-5H appeared as a singlet at
d 8.48. Similarly a singlet appeared at d 8.64 is due to –N‚CH
protons. Two singlets at d 12.75 and d 13.48 are due to pyrazole–
Figure 3 The best and stable conformations of all the synthesized molecules including the considered standard drug molecule. (A) 4a
forming 1H bond with Ser347. (B) 4b forming 2H bond with Thr352 and Glu488. (C) 4c forming 2H bond with Thr352 and Lys603. (D) 4d
forming 1H bond with Thr352. (E) 2a forming 0H bond. (F) 2b forming 0H bond. (G) Streptomycin forming 5H bond with Val399,
Cys300, Asp354 and Ala602 (2H bonds).
202 A.M. Vijesh et al.NH and imidazole–NH respectively further conﬁrms the struc-
ture. The mass spectrum of 4c showed molecular ion peak atm/
z= 402.0 (M+1), which is in agreement with themolecular for-
mula C17H15N5O3S2. Similarly the spectral values for all the
compounds and C, H, N analyses are given in the experimental
part and the characterization is provided in Table 1.
3.2. Antibacterial studies
The in vitro antibacterial activity of newly synthesized com-
pounds 2a,b and 4a-d was determined by well plate method.
The antibacterial screening revealed that some of the testedcompounds showed good inhibition against various tested
microbial strains. The result indicated that among the tested
compounds, 4c showed excellent activity against P. aerugin-
osa at concentrations of 1 and 0.5 mg/mL compared to stan-
dard drug streptomycin. 4c showed similar activity as that of
standard, against C. proﬁngens, at 1 and 0.5 mg/mL concen-
trations. Results of antibacterial studies have been presented
in Table 2.
As regards the relationships between the structure of the het-
erocyclic scaffold and the detected antibacterial properties, it
showed varied biological activity. Compound 4c has thioanisyl
moiety on pyrazole ring, which is accounted for the enhanced
Table 3 Binding Energy and Inhibition Constant of the
compounds (2a,b), (4a–d) and the standard drug Streptomycin.
Compound Binding Energy
(kJ mol1)
Inhibition
Constant (lM)
2a 7.57 2.81
2b 8.01 1.35
4a 6.99 7.47
4b 6.93 8.38
4c 6.91 8.56
4d 7.19 5.38
Streptomycin 6.72 11.82
Molecular docking studies of some new imidazole derivatives 203antibacterial activity. However in the ﬁrst series, compounds
showed moderate antimicrobial activity. Imidazole and pyrazole
nucleus which is present in both the series are responsible for the
biological activity. However the presence of other substituents is
responsible for the varied biological activity of the compounds.
3.3. Molecular docking studies
Considering the well obtained in vitro results, it was thought
worthy to perform molecular docking studies, hence screening
the compounds, inculcating both in silico and in vitro results.
Considering GlcN-6-P synthase as the target receptor, compar-
ative and automated docking studies with newly synthesized
candidate lead compounds was performed to determine the
best in silico conformation. The Lamarckian genetic algorithm,
inculcated in the docking program AutoDock 4.2, was em-
ployed to satisfy the purpose. Fig. 3 shows the native crystal
structure of GlcN-6-P synthase (X chain) in complex with glu-
cosamine-6-phosphate was obtained from Protein Data Bank
(http://www.pdb.org/pdb/home/home.do) with the PDB ID
2VF5 which was resolved at 2.90 A˚ using X-ray diffraction
(Mouilleron et al., 2008) (Fig. 1).
The docking of receptor GlcN-6-P with newly synthesized
candidate ligands exhibited well established bonds with one or
more amino acids in the receptor active pocket. The active pock-
et was considered to be the site where glucosamine-6-phosphate-
complexes in GlcN-6-Pof 2VF5. The active pocket consisted of
12 amino acid residues as Ala602, Val399, Ala400, Gly301,
Thr302, Ser303, Cys300, Gln348, Ser349, Thr352, Ser347 and
Lys603 as shown in Fig. 2. The synthesized ligand molecules
having 2D structure were converted to energy minimized 3D
structures and were further used for in silico protein–ligand
docking. All the six synthesized molecules were docked. Fig. 3
shows the docked images of selected candidate ligands including
the considered standard drug i.e. Streptomycin. Table 3 shows
the Binding Energy and Inhibition Constant of seven com-
pounds including the standard. In silico studies revealed all the
synthesized molecules showed good binding energy toward the
target protein ranging from 8.01 to 6.91 kJ mol1.
4. Conclusion
Six new imidazole derivatives were synthesized in reasonably
good yields. They were characterized by 1H NMR, 13C
NMR, mass spectrometry, IR studies and elemental analyses.
All the newly synthesized compounds were tested for antimi-
crobial activity by well plate method. Among the screened
samples, compound 4c has emerged as most active against
all tested microorganisms compared to the standard drug.Finally the molecular docking studies of the synthesized
compounds were carried out and the results of such studies
were reported. In silico studies revealed that all the synthesized
compounds 2a,b, 4a–d have relatively lesser binding energy as
compared to the standard drug and may be considered as a
good inhibitor of GlcN-6-P. Hence this study has widened
the scope of developing these imidazole derivatives as promis-
ing antibacterial agents.Acknowledgements
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